Form 4: Soleno Therapeutics Merger Completes, Executive Stock Options Exercised

Soleno Therapeutics, Inc. has completed its merger with Neocrine Biosciences, Inc., with executives receiving cash for vested and unvested stock options and common stock.

Summary

• Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc., reported transactions on May 18, 2026, related to the company's merger.
• The merger involved Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent"), and Sigma Merger Sub, Inc. ("Merger Sub").
• Following the merger, each outstanding vested and unvested Restricted Stock Unit (RSU) was cancelled and converted into the right to receive $53.00 in cash.
• Each outstanding share of the Company's Common Stock was also cancelled and converted into the right to receive $53.00 in cash.
• Stock options were cancelled in exchange for a cash payment equal to the difference between the $53.00 merger consideration and the per-share exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports on a completed merger and the resulting cash transactions for an executive, which is a standard regulatory event rather than an indicator of new performance or strategic shifts.

Positives

• The merger was successfully completed, providing a cash payout to shareholders and option holders.
• All outstanding common stock and RSUs were converted into a cash payment of $53.00 per share.
• Stock options were converted into cash payments, reflecting the value above their exercise price.

Negatives

• All outstanding equity awards (RSUs and stock options) were cancelled as part of the merger, meaning no continued equity participation in the combined entity for these individuals.
• The filing indicates a complete conversion to cash, suggesting no rollover equity for the reporting person in the acquiring entity.

Risks

• The filing does not explicitly detail risks associated with the merger itself, but the conversion of equity to cash implies a change in investment structure for the reporting person.
• Potential risks for shareholders and option holders would have been assessed prior to the merger agreement, but are not detailed in this Form 4.

Future Outlook

The filing is a report of completed transactions related to a merger and does not contain forward-looking statements or guidance for the combined entity. The future outlook for the reporting person is now tied to the cash received from the merger.

Management Comments

• The filing itself is a regulatory disclosure and does not contain direct management comments or opinions.
• The transaction details reflect the terms of the merger agreement, which was presumably approved by management and the board.

Industry Context

StockSavvy.ai notes that this Form 4 filing signifies the completion of a merger for Soleno Therapeutics, a common event in the biotechnology and pharmaceutical sectors where companies often merge or are acquired to consolidate pipelines, leverage resources, or achieve economies of scale. The cash-out structure for executives is typical in such acquisition scenarios.

Comparison to Industry Standards

• The $53.00 per share cash consideration is a specific valuation for Soleno Therapeutics, Inc. at the time of its acquisition by Neocrine Biosciences, Inc.
• The structure of converting stock options into a cash payment equal to the "in-the-money" value (Merger Consideration minus Exercise Price) is a standard practice in the industry for M&A transactions.
• The cancellation of RSUs and conversion to cash is also a common method for handling unvested equity awards in acquisitions, ensuring that employees are compensated for their service up to the merger date.

Stakeholder Impact

• Shareholders: Received $53.00 in cash per share, realizing their investment.
• Employees (including executives): Received cash for vested and unvested RSUs and stock options, with the amount dependent on the terms of their awards.
• Creditors: The merger structure implies the acquiring entity assumes liabilities, but specific impacts are not detailed in this filing.

Next Steps

• The reporting person, Michael F. Huang, has received cash for his equity holdings in Soleno Therapeutics, Inc.
• The combined entity, now a subsidiary of Neocrine Biosciences, Inc., will continue operations under the new ownership structure.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Form 4, SEC Filing, Stock Options, RSUs, Michael F. Huang, Clinical Development